fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Showing products 1–24 of 25. More products

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Amoxicillin & clavulanic acid

Form:

24 of 24 products shown

22 general benefit · 2 not a benefit

Clavulin · DIN 01916882 · 25 mg & 6.25 mg/mL · oral liquid

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
No interchangeable product listed in the Ontario extract
Clavulin · DIN 01916882 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 1996-10-01 Daily cost (source): $1.8975 Health Canada: Marketed since 2003-02-10 · brand CLAVULIN 125 F ORAL SUS · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Powder for suspension · route Oral · ingredients CLAVULANIC ACID (CLAVULANATE POTASSIUM) 31.25 MG/5ML, AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 125 MG/5ML · company Glaxosmithkline inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Clavulin: Formulary list price $0.13 per unit (the source does not state the unit; exact figure $0.1265). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01916882)

Source record
DIN 01916882: Clavulin Raw flags: sec3=Y Item: 081216054; group id 26; item number 0048; lccId None; manufacturer id GSK Source form: O/L; strength: 25mg & 6.25mg/mL Recorded listing: General benefit Source prices (unrounded): $0.1265; ministry $0.1265 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01916882 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15208
Shortage status: resolved shortage (ended June 20, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01916882
Shortage record checked October 6, 2026

Clavulin · DIN 01916874 · 50 mg & 12.5 mg/mL · oral liquid

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Clavulin · DIN 01916874 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 1996-10-01 Daily cost (source): $4.1295 Health Canada: Marketed since 2003-01-31 · brand CLAVULIN 250 F ORAL SUS · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Powder for suspension · route Oral · ingredients CLAVULANIC ACID (CLAVULANATE POTASSIUM) 62.5 MG/5ML, AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 250 MG/5ML · company Glaxosmithkline inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01916874)

Source record
DIN 01916874: Clavulin Raw flags: sec3=Y Item: 081216053; group id 26; item number 0049; lccId None; manufacturer id GSK Source form: O/L; strength: 50mg & 12.5mg/mL Recorded listing: General benefit Source prices (unrounded): $0.2753; ministry $0.1216 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01916874 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15209
Interchangeable products
Jamp Amoxi Clav Suspension · DIN 02539438 · $0.1216 M-Amoxi Clav · DIN 02542226 · $0.1216
Shortage status: resolved shortage (ended March 15, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01916874
Shortage record checked October 6, 2026

Jamp Amoxi Clav Suspension · DIN 02539438 · 50 mg & 12.5 mg/mL · oral liquid

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Amoxi Clav Suspension · DIN 02539438 Manufacturer: Jamp Pharma Corporation; listing date 2024-09-27 Daily cost (source): $1.8240 Health Canada: Marketed since 2024-07-22 · brand JAMP AMOXI CLAV SUSPENSION · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Powder for suspension · route Oral · ingredients AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 250 MG/5ML, CLAVULANIC ACID (CLAVULANATE POTASSIUM) 62.5 MG/5ML · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp Amoxi Clav Suspension: Formulary list price $0.12 per unit (the source does not state the unit; exact figure $0.1216). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02539438)

Source record
DIN 02539438: Jamp Amoxi Clav Suspension Raw flags: sec3=Y Item: 081216053; group id 26; item number 0049; lccId None; manufacturer id JPC Source form: O/L; strength: 50mg & 12.5mg/mL Recorded listing: General benefit Source prices (unrounded): $0.1216; ministry $0.1216 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02539438 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102818
Interchangeable products
Clavulin · DIN 01916874 · $0.1216 M-Amoxi Clav · DIN 02542226 · $0.1216
Shortage status: active shortage (reported March 12, 2026, estimated to end November 20, 2026, last updated September 21, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02539438
Shortage record checked October 6, 2026

M-Amoxi Clav · DIN 02542226 · 50 mg & 12.5 mg/mL · oral liquid

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
M-Amoxi Clav · DIN 02542226 Manufacturer: Mantra Pharma Inc.; listing date 2024-03-28 Daily cost (source): $1.8240 Health Canada: Marketed since 2024-02-01 · brand M-AMOXI CLAV · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Powder for suspension · route Oral · ingredients AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 250 MG/5ML, CLAVULANIC ACID (CLAVULANATE POTASSIUM) 62.5 MG/5ML · company Mantra pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

M-Amoxi Clav: Formulary list price $0.12 per unit (the source does not state the unit; exact figure $0.1216). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02542226)

Source record
DIN 02542226: M-Amoxi Clav Raw flags: sec3=Y Item: 081216053; group id 26; item number 0049; lccId None; manufacturer id MAT Source form: O/L; strength: 50mg & 12.5mg/mL Recorded listing: General benefit Source prices (unrounded): $0.1216; ministry $0.1216 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02542226 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103081
Interchangeable products
Clavulin · DIN 01916874 · $0.1216 Jamp Amoxi Clav Suspension · DIN 02539438 · $0.1216
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02542226
Shortage record checked October 6, 2026

Clavulin (BID) · DIN 02238831 · 200 mg & 28.5 mg/5 mL · suspension

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Clavulin (BID) · DIN 02238831 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2000-01-17 Health Canada: Marketed since 2003-01-15 · brand CLAVULIN 200 · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Powder for suspension · route Oral · ingredients AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 200 MG/5ML, CLAVULANIC ACID (CLAVULANATE POTASSIUM) 28.5 MG/5ML · company Glaxosmithkline inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02238831)

Source record
DIN 02238831: Clavulin (BID) Raw flags: sec3=Y Item: 081216081; group id 26; item number 0050; lccId None; manufacturer id GSK Source form: Susp; strength: 200mg & 28.5mg/5mL Recorded listing: General benefit Source prices (unrounded): $0.1974; ministry $0.1007 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02238831 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62269
Interchangeable products
Jamp Amoxi Clav Suspension · DIN 02539411 · $0.1007
Shortage status: resolved shortage (ended June 2, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02238831
Shortage record checked October 6, 2026

Apo-Amoxi Clav · DIN 02243350 · 250 mg & 125 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Apo-Amoxi Clav · DIN 02243350 Manufacturer: Apotex Inc.; listing date 2001-10-11 Daily cost (source): $0.7401 Health Canada: Marketed since 2020-02-10 · brand APO-AMOXI CLAV · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Tablet · route Oral · ingredients CLAVULANIC ACID (CLAVULANATE POTASSIUM) 125 MG, AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 250 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Amoxi Clav: Formulary list price $0.25 per unit (the source does not state the unit; exact figure $0.2467). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02243350)

Source record
DIN 02243350: Apo-Amoxi Clav Raw flags: sec3=Y Item: 081216052; group id 26; item number 0052; lccId None; manufacturer id APX Source form: Tab; strength: 250mg & 125mg Recorded listing: General benefit Source prices (unrounded): $0.2467; ministry $0.2467 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02243350 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67257
Interchangeable products
Auro-Amoxiclav · DIN 02471671 · $0.2467 Clavulin · DIN 01916866 · not recorded Jamp Amoxi Clav · DIN 02508249 · $0.2467
Shortage status: shortage reported ended April 23, 2026 (report last updated April 23, 2026); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02243350
Shortage record checked October 6, 2026

Auro-Amoxiclav · DIN 02471671 · 250 mg & 125 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Auro-Amoxiclav · DIN 02471671 Manufacturer: Auro Pharma Inc.; listing date 2022-04-29 Daily cost (source): $0.7401 Health Canada: Marketed since 2022-03-03 · brand AURO-AMOXICLAV · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Tablet · route Oral · ingredients AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 250 MG, CLAVULANIC ACID (CLAVULANATE POTASSIUM) 125 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Auro-Amoxiclav: Formulary list price $0.25 per unit (the source does not state the unit; exact figure $0.2467). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02471671)

Source record
DIN 02471671: Auro-Amoxiclav Raw flags: sec3=Y Item: 081216052; group id 26; item number 0052; lccId None; manufacturer id AUR Source form: Tab; strength: 250mg & 125mg Recorded listing: General benefit Source prices (unrounded): $0.2467; ministry $0.2467 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02471671 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96090
Interchangeable products
Apo-Amoxi Clav · DIN 02243350 · $0.2467 Clavulin · DIN 01916866 · not recorded Jamp Amoxi Clav · DIN 02508249 · $0.2467
Shortage status: resolved shortage (ended February 18, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02471671
Shortage record checked October 6, 2026

Jamp Amoxi Clav · DIN 02508249 · 250 mg & 125 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Jamp Amoxi Clav · DIN 02508249 Manufacturer: Jamp Pharma Corporation; listing date 2022-02-28 Daily cost (source): $0.7401 Health Canada: Marketed since 2021-12-24 · brand JAMP AMOXI CLAV · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Tablet · route Oral · ingredients CLAVULANIC ACID (CLAVULANATE POTASSIUM) 125 MG, AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 250 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp Amoxi Clav: Formulary list price $0.25 per unit (the source does not state the unit; exact figure $0.2467). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02508249)

Source record
DIN 02508249: Jamp Amoxi Clav Raw flags: sec3=Y Item: 081216052; group id 26; item number 0052; lccId None; manufacturer id JPC Source form: Tab; strength: 250mg & 125mg Recorded listing: General benefit Source prices (unrounded): $0.2467; ministry $0.2467 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02508249 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99763
Interchangeable products
Apo-Amoxi Clav · DIN 02243350 · $0.2467 Auro-Amoxiclav · DIN 02471671 · $0.2467 Clavulin · DIN 01916866 · not recorded
Shortage status: resolved shortage (ended April 17, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02508249
Shortage record checked October 6, 2026

Clavulin (BID) · DIN 02238830 · 400 mg & 57 mg/5 mL · suspension

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Clavulin (BID) · DIN 02238830 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2000-01-17 Health Canada: Marketed since 2002-12-17 · brand CLAVULIN 400 · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Powder for suspension · route Oral · ingredients CLAVULANIC ACID (CLAVULANATE POTASSIUM) 57 MG/5ML, AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 400 MG/5ML · company Glaxosmithkline inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02238830)

Source record
DIN 02238830: Clavulin (BID) Raw flags: sec3=Y Item: 081216082; group id 26; item number 0051; lccId None; manufacturer id GSK Source form: Susp; strength: 400mg & 57mg/5mL Recorded listing: General benefit Source prices (unrounded): $0.3850; ministry $0.1591 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02238830 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62268
Interchangeable products
Jamp Amoxi Clav Suspension · DIN 02539446 · $0.1591 M-Amoxi Clav · DIN 02530694 · $0.1591
Shortage status: resolved shortage (ended March 15, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02238830
Shortage record checked October 6, 2026

Jamp Amoxi Clav Suspension · DIN 02539446 · 400 mg & 57 mg/5 mL · suspension

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Amoxi Clav Suspension · DIN 02539446 Manufacturer: Jamp Pharma Corporation; listing date 2024-09-27 Health Canada: Marketed since 2024-07-22 · brand JAMP AMOXI CLAV SUSPENSION · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Powder for suspension · route Oral · ingredients AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 400 MG/5ML, CLAVULANIC ACID (CLAVULANATE POTASSIUM) 57 MG/5ML · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp Amoxi Clav Suspension: Formulary list price $0.16 per unit (the source does not state the unit; exact figure $0.1591). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02539446)

Source record
DIN 02539446: Jamp Amoxi Clav Suspension Raw flags: sec3=Y Item: 081216082; group id 26; item number 0051; lccId None; manufacturer id JPC Source form: Susp; strength: 400mg & 57mg/5mL Recorded listing: General benefit Source prices (unrounded): $0.1591; ministry $0.1591 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02539446 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102819
Interchangeable products
Clavulin (BID) · DIN 02238830 · $0.1591 M-Amoxi Clav · DIN 02530694 · $0.1591
Shortage status: active shortage (reported June 30, 2026, estimated to end September 28, 2026, last updated September 21, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02539446
Shortage record checked October 6, 2026

M-Amoxi Clav · DIN 02530694 · 400 mg & 57 mg/5 mL · suspension

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
M-Amoxi Clav · DIN 02530694 Manufacturer: Mantra Pharma Inc.; listing date 2022-12-21 Health Canada: Marketed since 2022-11-24 · brand M-AMOXI CLAV · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Powder for suspension · route Oral · ingredients AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 400 MG/5ML, CLAVULANIC ACID (CLAVULANATE POTASSIUM) 57 MG/5ML · company Mantra pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

M-Amoxi Clav: Formulary list price $0.16 per unit (the source does not state the unit; exact figure $0.1591). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02530694)

Source record
DIN 02530694: M-Amoxi Clav Raw flags: sec3=Y Item: 081216082; group id 26; item number 0051; lccId None; manufacturer id MAT Source form: Susp; strength: 400mg & 57mg/5mL Recorded listing: General benefit Source prices (unrounded): $0.1591; ministry $0.1591 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02530694 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101985
Interchangeable products
Clavulin (BID) · DIN 02238830 · $0.1591 Jamp Amoxi Clav Suspension · DIN 02539446 · $0.1591
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02530694
Shortage record checked October 6, 2026

Amoxicillin/Clav · DIN 02536021 · 500 mg & 125 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Amoxicillin/Clav · DIN 02536021 Manufacturer: Sanis Health Inc.; listing date 2024-04-30 Daily cost (source): $1.1334 Health Canada: Marketed since 2024-02-20 · brand AMOXICILLIN/CLAV · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Tablet · route Oral · ingredients AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 500 MG, CLAVULANIC ACID (CLAVULANATE POTASSIUM) 125 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Amoxicillin/Clav: Formulary list price $0.38 per unit (the source does not state the unit; exact figure $0.3778). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02536021)

Source record
DIN 02536021: Amoxicillin/Clav Raw flags: sec3=Y Item: 081216051; group id 26; item number 0053; lccId None; manufacturer id SAI Source form: Tab; strength: 500mg & 125mg Recorded listing: General benefit Source prices (unrounded): $0.3778; ministry $0.3778 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02536021 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102484
Interchangeable products
Apo-Amoxi Clav · DIN 02243351 · $0.3778 Auro-Amoxiclav · DIN 02471698 · $0.3778 Clavulin · DIN 01916858 · not recorded Jamp Amoxi Clav · DIN 02508257 · $0.3778 Sandoz Amoxi-Clav Tablets · DIN 02482576 · $0.3778
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02536021
Shortage record checked October 6, 2026

Apo-Amoxi Clav · DIN 02243351 · 500 mg & 125 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Apo-Amoxi Clav · DIN 02243351 Manufacturer: Apotex Inc.; listing date 2001-10-11 Daily cost (source): $1.1334 Health Canada: Marketed since 2020-02-10 · brand APO-AMOXI CLAV · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Tablet · route Oral · ingredients AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 500 MG, CLAVULANIC ACID (CLAVULANATE POTASSIUM) 125 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Amoxi Clav: Formulary list price $0.38 per unit (the source does not state the unit; exact figure $0.3778). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02243351)

Source record
DIN 02243351: Apo-Amoxi Clav Raw flags: sec3=Y Item: 081216051; group id 26; item number 0053; lccId None; manufacturer id APX Source form: Tab; strength: 500mg & 125mg Recorded listing: General benefit Source prices (unrounded): $0.3778; ministry $0.3778 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02243351 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67258
Interchangeable products
Amoxicillin/Clav · DIN 02536021 · $0.3778 Auro-Amoxiclav · DIN 02471698 · $0.3778 Clavulin · DIN 01916858 · not recorded Jamp Amoxi Clav · DIN 02508257 · $0.3778 Sandoz Amoxi-Clav Tablets · DIN 02482576 · $0.3778
Shortage status: resolved shortage (ended June 19, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02243351
Shortage record checked October 6, 2026

Auro-Amoxiclav · DIN 02471698 · 500 mg & 125 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Auro-Amoxiclav · DIN 02471698 Manufacturer: Auro Pharma Inc.; listing date 2022-04-29 Daily cost (source): $1.1334 Health Canada: Marketed since 2022-03-03 · brand AURO-AMOXICLAV · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Tablet · route Oral · ingredients AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 500 MG, CLAVULANIC ACID (CLAVULANATE POTASSIUM) 125 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Auro-Amoxiclav: Formulary list price $0.38 per unit (the source does not state the unit; exact figure $0.3778). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02471698)

Source record
DIN 02471698: Auro-Amoxiclav Raw flags: sec3=Y Item: 081216051; group id 26; item number 0053; lccId None; manufacturer id AUR Source form: Tab; strength: 500mg & 125mg Recorded listing: General benefit Source prices (unrounded): $0.3778; ministry $0.3778 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02471698 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96091
Interchangeable products
Amoxicillin/Clav · DIN 02536021 · $0.3778 Apo-Amoxi Clav · DIN 02243351 · $0.3778 Clavulin · DIN 01916858 · not recorded Jamp Amoxi Clav · DIN 02508257 · $0.3778 Sandoz Amoxi-Clav Tablets · DIN 02482576 · $0.3778
Shortage status: resolved shortage (ended February 18, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02471698
Shortage record checked October 6, 2026

Jamp Amoxi Clav · DIN 02508257 · 500 mg & 125 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Jamp Amoxi Clav · DIN 02508257 Manufacturer: Jamp Pharma Corporation; listing date 2022-02-28 Daily cost (source): $1.1334 Health Canada: Marketed since 2021-12-24 · brand JAMP AMOXI CLAV · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Tablet · route Oral · ingredients AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 500 MG, CLAVULANIC ACID (CLAVULANATE POTASSIUM) 125 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp Amoxi Clav: Formulary list price $0.38 per unit (the source does not state the unit; exact figure $0.3778). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02508257)

Source record
DIN 02508257: Jamp Amoxi Clav Raw flags: sec3=Y Item: 081216051; group id 26; item number 0053; lccId None; manufacturer id JPC Source form: Tab; strength: 500mg & 125mg Recorded listing: General benefit Source prices (unrounded): $0.3778; ministry $0.3778 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02508257 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99764
Interchangeable products
Amoxicillin/Clav · DIN 02536021 · $0.3778 Apo-Amoxi Clav · DIN 02243351 · $0.3778 Auro-Amoxiclav · DIN 02471698 · $0.3778 Clavulin · DIN 01916858 · not recorded Sandoz Amoxi-Clav Tablets · DIN 02482576 · $0.3778
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02508257
Shortage record checked October 6, 2026

Sandoz Amoxi-Clav Tablets · DIN 02482576 · 500 mg & 125 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Sandoz Amoxi-Clav Tablets · DIN 02482576 Manufacturer: Sandoz Canada Inc.; listing date 2019-04-30 Daily cost (source): $1.1334 Health Canada: Marketed since 2019-03-01 · brand SANDOZ AMOXI-CLAV TABLET · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Tablet · route Oral · ingredients AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 500 MG, CLAVULANIC ACID (CLAVULANATE POTASSIUM) 125 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Sandoz Amoxi-Clav Tablets: Formulary list price $0.38 per unit (the source does not state the unit; exact figure $0.3778). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02482576)

Source record
DIN 02482576: Sandoz Amoxi-Clav Tablets Raw flags: sec3=Y Item: 081216051; group id 26; item number 0053; lccId None; manufacturer id SDZ Source form: Tab; strength: 500mg & 125mg Recorded listing: General benefit Source prices (unrounded): $0.3778; ministry $0.3778 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02482576 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97300
Interchangeable products
Amoxicillin/Clav · DIN 02536021 · $0.3778 Apo-Amoxi Clav · DIN 02243351 · $0.3778 Auro-Amoxiclav · DIN 02471698 · $0.3778 Clavulin · DIN 01916858 · not recorded Jamp Amoxi Clav · DIN 02508257 · $0.3778
Shortage status: resolved shortage (ended January 27, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02482576
Shortage record checked October 6, 2026

Amoxicillin/Clav · DIN 02536048 · 875 mg & 125 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Amoxicillin/Clav · DIN 02536048 Manufacturer: Sanis Health Inc.; listing date 2024-04-30 Health Canada: Marketed since 2024-02-20 · brand AMOXICILLIN/CLAV · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Tablet · route Oral · ingredients CLAVULANIC ACID (CLAVULANATE POTASSIUM) 125 MG, AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 875 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Amoxicillin/Clav: Formulary list price $0.56 per unit (the source does not state the unit; exact figure $0.5551). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02536048)

Source record
DIN 02536048: Amoxicillin/Clav Raw flags: sec3=Y Item: 081216080; group id 26; item number 0054; lccId None; manufacturer id SAI Source form: Tab; strength: 875mg & 125mg Recorded listing: General benefit Source prices (unrounded): $0.5551; ministry $0.5551 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02536048 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102485
Interchangeable products
Apo-Amoxi Clav · DIN 02245623 · $0.5551 Auro-Amoxiclav · DIN 02471701 · $0.5551 Clavulin (BID) · DIN 02238829 · not recorded Jamp Amoxi Clav · DIN 02508265 · $0.5551 Sandoz Amoxi-Clav Tablets · DIN 02482584 · $0.5551
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02536048
Shortage record checked October 6, 2026

Apo-Amoxi Clav · DIN 02245623 · 875 mg & 125 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Apo-Amoxi Clav · DIN 02245623 Manufacturer: Apotex Inc.; listing date 2003-09-04 Health Canada: Marketed since 2019-07-03 · brand APO-AMOXI CLAV · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Tablet · route Oral · ingredients AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 875 MG, CLAVULANIC ACID (CLAVULANATE POTASSIUM) 125 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Amoxi Clav: Formulary list price $0.56 per unit (the source does not state the unit; exact figure $0.5551). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02245623)

Source record
DIN 02245623: Apo-Amoxi Clav Raw flags: sec3=Y Item: 081216080; group id 26; item number 0054; lccId None; manufacturer id APX Source form: Tab; strength: 875mg & 125mg Recorded listing: General benefit Source prices (unrounded): $0.5551; ministry $0.5551 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02245623 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69723
Interchangeable products
Amoxicillin/Clav · DIN 02536048 · $0.5551 Auro-Amoxiclav · DIN 02471701 · $0.5551 Clavulin (BID) · DIN 02238829 · not recorded Jamp Amoxi Clav · DIN 02508265 · $0.5551 Sandoz Amoxi-Clav Tablets · DIN 02482584 · $0.5551
Shortage status: resolved shortage (ended April 4, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02245623
Shortage record checked October 6, 2026

Auro-Amoxiclav · DIN 02471701 · 875 mg & 125 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Auro-Amoxiclav · DIN 02471701 Manufacturer: Auro Pharma Inc.; listing date 2022-04-29 Health Canada: Marketed since 2022-03-03 · brand AURO-AMOXICLAV · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Tablet · route Oral · ingredients AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 875 MG, CLAVULANIC ACID (CLAVULANATE POTASSIUM) 125 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Auro-Amoxiclav: Formulary list price $0.56 per unit (the source does not state the unit; exact figure $0.5551). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02471701)

Source record
DIN 02471701: Auro-Amoxiclav Raw flags: sec3=Y Item: 081216080; group id 26; item number 0054; lccId None; manufacturer id AUR Source form: Tab; strength: 875mg & 125mg Recorded listing: General benefit Source prices (unrounded): $0.5551; ministry $0.5551 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02471701 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96092
Interchangeable products
Amoxicillin/Clav · DIN 02536048 · $0.5551 Apo-Amoxi Clav · DIN 02245623 · $0.5551 Clavulin (BID) · DIN 02238829 · not recorded Jamp Amoxi Clav · DIN 02508265 · $0.5551 Sandoz Amoxi-Clav Tablets · DIN 02482584 · $0.5551
Shortage status: resolved shortage (ended December 16, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02471701
Shortage record checked October 6, 2026

Jamp Amoxi Clav · DIN 02508265 · 875 mg & 125 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Jamp Amoxi Clav · DIN 02508265 Manufacturer: Jamp Pharma Corporation; listing date 2022-02-28 Health Canada: Marketed since 2021-12-24 · brand JAMP AMOXI CLAV · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Tablet · route Oral · ingredients AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 875 MG, CLAVULANIC ACID (CLAVULANATE POTASSIUM) 125 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp Amoxi Clav: Formulary list price $0.56 per unit (the source does not state the unit; exact figure $0.5551). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02508265)

Source record
DIN 02508265: Jamp Amoxi Clav Raw flags: sec3=Y Item: 081216080; group id 26; item number 0054; lccId None; manufacturer id JPC Source form: Tab; strength: 875mg & 125mg Recorded listing: General benefit Source prices (unrounded): $0.5551; ministry $0.5551 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02508265 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99765
Interchangeable products
Amoxicillin/Clav · DIN 02536048 · $0.5551 Apo-Amoxi Clav · DIN 02245623 · $0.5551 Auro-Amoxiclav · DIN 02471701 · $0.5551 Clavulin (BID) · DIN 02238829 · not recorded Sandoz Amoxi-Clav Tablets · DIN 02482584 · $0.5551
Shortage status: resolved shortage (ended May 31, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02508265
Shortage record checked October 6, 2026

Sandoz Amoxi-Clav Tablets · DIN 02482584 · 875 mg & 125 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Sandoz Amoxi-Clav Tablets · DIN 02482584 Manufacturer: Sandoz Canada Inc.; listing date 2019-04-30 Health Canada: Marketed since 2019-03-01 · brand SANDOZ AMOXI-CLAV TABLET · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Tablet · route Oral · ingredients CLAVULANIC ACID (CLAVULANATE POTASSIUM) 125 MG, AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 875 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Sandoz Amoxi-Clav Tablets: Formulary list price $0.56 per unit (the source does not state the unit; exact figure $0.5551). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02482584)

Source record
DIN 02482584: Sandoz Amoxi-Clav Tablets Raw flags: sec3=Y Item: 081216080; group id 26; item number 0054; lccId None; manufacturer id SDZ Source form: Tab; strength: 875mg & 125mg Recorded listing: General benefit Source prices (unrounded): $0.5551; ministry $0.5551 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02482584 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97301
Interchangeable products
Amoxicillin/Clav · DIN 02536048 · $0.5551 Apo-Amoxi Clav · DIN 02245623 · $0.5551 Auro-Amoxiclav · DIN 02471701 · $0.5551 Clavulin (BID) · DIN 02238829 · not recorded Jamp Amoxi Clav · DIN 02508265 · $0.5551
Shortage status: resolved shortage (ended November 28, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02482584
Shortage record checked October 6, 2026

Jamp Amoxi Clav Suspension · DIN 02539411 · 200 mg & 28.5 mg/5 mL · suspension

General benefitDormant since August 3, 2026 · checked October 5, 2026 · What does dormant mean?
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Jamp Amoxi Clav Suspension · DIN 02539411 Manufacturer: Jamp Pharma Corporation; listing date 2024-09-27 Health Canada: Dormant since 2026-08-03 · brand JAMP AMOXI CLAV SUSPENSION · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Powder for suspension · route Oral · ingredients AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 200 MG/5ML, CLAVULANIC ACID (CLAVULANATE POTASSIUM) 28.5 MG/5ML · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp Amoxi Clav Suspension: Formulary list price $0.10 per unit (the source does not state the unit; exact figure $0.1007). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02539411)

Source record
DIN 02539411: Jamp Amoxi Clav Suspension Raw flags: sec3=Y Item: 081216081; group id 26; item number 0050; lccId None; manufacturer id JPC Source form: Susp; strength: 200mg & 28.5mg/5mL Recorded listing: General benefit Source prices (unrounded): $0.1007; ministry $0.1007 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02539411 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102817
Interchangeable products
Clavulin (BID) · DIN 02238831 · $0.1007
Shortage status: active shortage (reported December 23, 2024, estimated to end September 28, 2026, last updated September 22, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02539411
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since August 3, 2026 — choose a marketed DIN from the same-category list.

Clavulin · DIN 01916866 · 250 mg & 125 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2007-08-02 — choose a marketed DIN from the same-category list.Discontinued August 2, 2007 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2007-08-02 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2007-08-02 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Clavulin · DIN 01916866 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 1996-10-01 Daily cost (source): $0.7401 Health Canada: Cancelled post market since 2007-08-02 · brand CLAVULIN 250 TAB · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Tablet · route Oral · ingredients CLAVULANIC ACID (CLAVULANATE POTASSIUM) 125 MG, AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 250 MG · company Glaxosmithkline inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Clavulin: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01916866)

Source record
DIN 01916866: Clavulin Raw flags: notABenefit=Y, sec3=Y Item: 081216052; group id 26; item number 0052; lccId None; manufacturer id GSK Source form: Tab; strength: 250mg & 125mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01916866 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18891
Interchangeable products
Apo-Amoxi Clav · DIN 02243350 · $0.2467 Auro-Amoxiclav · DIN 02471671 · $0.2467 Jamp Amoxi Clav · DIN 02508249 · $0.2467
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01916866
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since August 2, 2007 — choose a marketed DIN from the same-category list.

Clavulin · DIN 01916858 · 500 mg & 125 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2024-01-13 — choose a marketed DIN from the same-category list.Discontinued January 13, 2024 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2024-01-13 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2024-01-13 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
1 brand, same coverage
Clavulin · DIN 01916858 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 1996-10-01 Daily cost (source): $1.1334 Health Canada: Cancelled post market since 2024-01-13 · brand CLAVULIN 500 F TAB · ATC J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR · form Tablet · route Oral · ingredients AMOXICILLIN (AMOXICILLIN TRIHYDRATE) 500 MG, CLAVULANIC ACID (CLAVULANATE POTASSIUM) 125 MG · company Glaxosmithkline inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Clavulin: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01916858)

Source record
DIN 01916858: Clavulin Raw flags: notABenefit=Y, sec3=Y Item: 081216051; group id 26; item number 0053; lccId None; manufacturer id GSK Source form: Tab; strength: 500mg & 125mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01916858 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15903
Interchangeable products
Amoxicillin/Clav · DIN 02536021 · $0.3778 Apo-Amoxi Clav · DIN 02243351 · $0.3778 Auro-Amoxiclav · DIN 02471698 · $0.3778 Jamp Amoxi Clav · DIN 02508257 · $0.3778 Sandoz Amoxi-Clav Tablets · DIN 02482576 · $0.3778
Shortage status: discontinued (January 31, 2024, reported by GLAXOSMITHKLINE INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01916858
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since January 13, 2024 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (J01C, J01CR): coverage varies; not interchangeable

  • Piperacillin + tazobactam (Tazocin): not a benefit
  • Amoxicillin (Novamoxin): general benefit, not a benefit, listing status unconfirmed
  • Ampicillin (Penbritin): general benefit, not a benefit
  • Cloxacillin (Orbenin): general benefit, not a benefit
  • Penicillin v (Nadopen-V): general benefit, not a benefit
Other drugs in the same formulary class (08:12:16 Penicillins) and how they are covered

Matched class: 08:12:16 Penicillins

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Some products covered without a code (check the product listing): AMOXICILLIN, AMPICILLIN, CLOXACILLIN, PENICILLIN V (POTASSIUM) 08:12:16 Penicillins

PIPERACILLIN SODIUM & TAZOBACTAM SODIUM

· 18 products · Off-Formulary Interchangeable, not an ODB benefit (16), Off-Formulary Interchangeable, not an ODB benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (2) · strengths: 2g & 250mg, 3g & 375mg, 4g & 500mg · Inj Pd-2.25g Vial Pk, Inj Pd-3.375g Vial Pk, Inj Pd-4.5g Vial Pk

AMOXICILLIN

· 36 products · General benefit (27), Listed, not a benefit (4), Off-Formulary Interchangeable, not an ODB benefit (4), Temporary benefit (1) · strengths: 250mg, 500mg, 125mg, 25mg/mL, 50mg/mL · Cap, Chew Tab, O/L, Pd for Oral Susp

AMPICILLIN

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 250mg, 500mg · Cap

CLOXACILLIN

· 8 products · Listed, not a benefit (3), General benefit (5) · strengths: 250mg, 500mg, 25mg/mL · Cap, O/L

PENICILLIN V (POTASSIUM)

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 25mg/mL, 300mg · O/L, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 08:12:16
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:24 Tetracyclines, 08:12:28 Other Antibiotics, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: lower respiratory tract infections
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. CEFOXITIN SODIUM · Off-Formulary Interchangeable, not an ODB benefit 5 - Lower respiratory tract infections PM: https://pdf.hres.ca/dpd_pm/00073366.PDF; date November 16, 2023; DIN 02128187; fetched 2026-09-10 Product monograph CEFTRIAXONE DISODIUM · Listed, not a benefit (3), General benefit (9), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1), Off-Formulary Interchangeable, not an ODB benefit (3) • Lower Respiratory tract infections caused by E. coli, H. influenzae, K. pneumoniae and species, Staph. aureus, Strep. pneumoniae and species (excluding enterococci). PM: https://pdf.hres.ca/dpd_pm/00071552.PDF; date MAY 15, 2023; DIN 02289695; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
1. Indications CLAVULIN (amoxicillin / clavulanate potassium) is indicated for the treatment of the following infections when caused by CLAVULIN-susceptible strains of the designated bacteria: • Sinusitis when caused by β-lactamase producing strains of H. influenzae or Moraxella (Branhamella) catarrhalis. • Otitis Media when caused by β-lactamase producing strains of H. influenzae or Moraxella (Branhamella) catarrhalis. • Lower Respiratory Tract Infections when caused by β-lactamase producing strains of H. influenzae, K. pneumoniae, S. aureus or Moraxella (Branhamella) catarrhalis. • Skin and Soft Tissue Infections when caused by β-lactamase producing strains of S. aureus. • Urinary Tract Infections when caused by β-lactamase producing strains of E. coli. While CLAVULIN is indicated only for the conditions listed above, infections caused by ampicillin (amoxicillin) susceptible organisms are also amenable to CLAVULIN treatment due to its amoxicillin content. Furthermore, mixed infections caused by organisms susceptible to ampicillin (amoxicillin) and β-lactamase producing organisms susceptible to CLAVULIN should not require the addition of another an… https://pdf.hres.ca/dpd_pm/00084428.PDF PM date: 2026-04-24 Source product: CLAVULIN 250 F ORAL SUS; DIN 01916874; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Jamp Amoxi Clav Suspension · DIN 02539438 Shortage status: active shortage (reported 2026-03-12, estimated to end 2026-11-20, last updated 2026-09-21); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02539438

Check this DIN again

Apo-Amoxi Clav · DIN 02243350 Shortage status: shortage reported ended 2026-04-23 (report last updated 2026-04-23); confirm supply with the pharmacy; reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02243350

Check this DIN again

Jamp Amoxi Clav Suspension · DIN 02539446 Shortage status: active shortage (reported 2026-06-30, estimated to end 2026-09-28, last updated 2026-09-21); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02539446

Check this DIN again

Jamp Amoxi Clav Suspension · DIN 02539411 Shortage status: active shortage (reported 2024-12-23, estimated to end 2026-09-28, last updated 2026-09-22); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02539411

Check this DIN again

Clavulin · DIN 01916858 Shortage status: discontinued (2024-01-31, reported by GLAXOSMITHKLINE INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01916858

Check this DIN again
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, September 10, 2026 ↗)

Other review policies

For Clavulin: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026